Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP-3180 PK and ORFM Evaluation in Healthy Volunteers
NCT02098187Phase 1Completed
- Sponsor
- MediBeacon
- Start
- Mar 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of relmapirazin in acute kidney injury (AKI) (4 arms), sponsored by MediBeacon. Primary endpoints: Total plasma clearance of MP-3180 and iohexol, Renal clearance of MP-3180 and iohexol and 5 more. Started Mar 2014; status: completed.
02
Drugs
relmapirazin
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT02098187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098187.